Three companies launch gene therapy alliance for eye diseases
Today, the companies officially announced the launch of the GEAR partnership (Evaluation of Adeno-Associated Virus Vector Gene Therapy for the...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...
Nordic Bioproducts Group opens its first production facility
Nordic Bioproduct’s commercial-scale manufacturing site is expected to create €40m in revenue in the first full operating year. In...
Bioplastics production capacity to quadruple by 2028
Global production capacity for bioplastics will almost quadruple within the next five years, according to estimates of the Nova Institute on behalf...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...